TScan Therapeutics, a Waltham, Mass.-based company dedicated to creating life-changing T cell therapies for patients, completed its $35m Series B funding.
Backers included Novartis Institutes for BioMedical Research (NIBR), Pitango Venture Capital, Astellas Venture Management (the wholly-owned venture capital organization of Astellas Pharma Inc), 6 Dimensions Capital, Longwood Fund, Bessemer Venture Partners, GV, and Novartis Venture Fund.
With this round, TScan has raised approximately $60m in total funding.
The company intends to use the funds to expand its development efforts.
Led by David P. Southwell, President and Chief Executive Officer, TScan designs therapies that reprogram a patient’s own T cells to recognize and fight their cancer using naturally-occurring TCRs that find and destroy shared cancer targets. The technology process allows TCRs to be scanned against target antigens in a genome-wide, high-throughput, and unbiased fashion. The company is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors, and has already discovered, through this process, novel antigens from TCRs, novel TCRs from known antigens, and previously uncharacterized off-targets of known TCRs.